Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.

Background: People who use drugs (PWUD) frequently delay or avoid obtaining medical care in traditional healthcare settings. Through a randomized controlled trial, we investigated facilitated telemedicine for hepatitis C virus (HCV) integrated into opioid treatment programmes. We sought to understan...

Descripción completa

Detalles Bibliográficos
Publicado en:Health Expectations Vol. 26; no. 6; pp. 2594 - 2608
Autores principales: Talal, Andrew H., Jaanimägi, Urmo, Dharia, Arpan, Dickerson, Suzanne S.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Dec2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=173516556&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 173516556
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        13696513
        EVY
      jtl: Health Expectations
      issn: 13696513
      maglogo: Y
    pubinfo:
      dt: Dec2023
      vid: 26
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        173516556
        170729648
        173516556
        173516556
        10.1111/hex.13854
        173516556
      ppf: 2594
      ppct: 14
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
      aug:
        au:
          Talal, Andrew H.
          Jaanimägi, Urmo
          Dharia, Arpan
          Dickerson, Suzanne S.
        affil: Department of Medicine, Jacobs School of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University at Buffalo, Buffalo New York,, USA
      sug:
        subj:
          Patient Attitudes Evaluation
          Life Experiences Evaluation
          Persons with Substance Use Disorders Psychosocial Factors
          Telemedicine
          Hepatitis C Therapy
          Substance Use Disorders Therapy
          Narcotics
          Health Care Delivery, Integrated
          Funding Source
          Human
          Purposive Sample
          Interviews
          Patient Centered Care
          Thematic Analysis
          Stigma
          Shame
          Self-Awareness
          Confidence
          Life Style Changes
          New York
          Methadone Therapeutic Use
          Buprenorphine Therapeutic Use
          Behavior Therapy
          Combined Modality Therapy
          Phenomenological Research
          Case Management
          Attitude to Illness
          Social Attitudes
          Health Services Accessibility
          Trust
      ab: Background: People who use drugs (PWUD) frequently delay or avoid obtaining medical care in traditional healthcare settings. Through a randomized controlled trial, we investigated facilitated telemedicine for hepatitis C virus (HCV) integrated into opioid treatment programmes. We sought to understand the experiences and meanings of facilitated telemedicine and an HCV cure among PWUD. Methods: We utilized purposive sampling to interview 25 participants, 6–40 months after achieving an HCV cure. We interpreted and explicated common meanings of participants' experiences of an HCV cure obtained through facilitated telemedicine. Results: Participants embraced facilitated telemedicine integrated into opioid treatment programmes as patient‐centred care delivered in 'safe spaces' (Theme 1). Participants elucidated their experiences of substance use and HCV while committing to treatment for both entities. Facilitated telemedicine integrated into opioid treatment programmes enabled participants to avoid stigma encountered in conventional healthcare settings (Theme 2). Participants conveyed facing negative perceptions of HCV and substance use disorder. Improved self‐awareness, acquired through HCV and substance use treatment, enabled participants to develop strategies to address shame and stigma (Theme 3). An HCV cure, considered by PWUD as a victory over a lethal infectious disease, promotes self‐confidence, enabling participants to improve their health and lives (Theme 4). Conclusions: Integrating facilitated telemedicine into opioid treatment programmes addresses several healthcare barriers for PWUD. Similarly, obtaining an HCV cure increases their self‐confidence, permissive to positive lifestyle changes and mitigating the negative consequences of substance use. Patient and Public Contribution: In this study of patient involvement, we interviewed patient‐participants to understand the meaning of an HCV cure through facilitated telemedicine. Participants from a facilitated telemedicine pilot study provided essential input on the design and outcomes of a randomized controlled trial. Pilot study participants endorsed facilitated telemedicine in a testimonial video. They attended site initiation meetings to guide trial implementation. A Patient Advisory Committee (PAC) ensured that patient participants were active members of the research team. The PAC represented patients' voices through feedback on study procedures. A Sustainability Committee supported public involvement in the research process, including educational opportunities, feedback on implementation, and future sustainability considerations.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N